title: Bevacizumab in the management of solid tumors.
abstract: Angiogenesis is defined as the formation of new blood vessels from a pre-existing vascular bed. By supplying nutrients and oxygen and removing waste products in malignant tumors, it is an essential process that regulates cancer growth and dissemination. This process is regulated by both pro- and antiangiogenic compounds. Vascular endothelial growth factor is one of the most important and best-studied proangiogenic factors. Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, has been shown to inhibit angiogenesis and is proving to be of clinical benefit in a variety of tumor types. The strongest evidence comes from studies in advanced colorectal and non-small-cell lung cancer, with growing evidence in breast and epithelial ovarian tumors. The duration and timing of bevacizumab's use is currently the focus of several ongoing clinical trials.
authors.affiliation: University of Southern California, Keck School of Medicine, Los Angeles, CA 90033, USA. panares@usc.edu
authors.forename: Roy L
authors.initials: RL
authors.lastname: Pañares
authors.forename: Agustin A
authors.initials: AA
authors.lastname: Garcia
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000453:epidemiology; D042461:Vascular Endothelial Growth Factor A / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab